Global DNA Repair Drugs Market Growth 2025-2031
Description
The global DNA Repair Drugs market size is predicted to grow from US$ 962 million in 2025 to US$ 2743 million in 2031; it is expected to grow at a CAGR of 19.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “DNA Repair Drugs Industry Forecast” looks at past sales and reviews total world DNA Repair Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected DNA Repair Drugs sales for 2025 through 2031. With DNA Repair Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DNA Repair Drugs industry.
This Insight Report provides a comprehensive analysis of the global DNA Repair Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on DNA Repair Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global DNA Repair Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DNA Repair Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DNA Repair Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of DNA Repair Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
PARP Inhibitors
Other
Segmentation by Application:
Oncological
Stroke
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Key Questions Addressed in this Report
What is the 10-year outlook for the global DNA Repair Drugs market?
What factors are driving DNA Repair Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do DNA Repair Drugs market opportunities vary by end market size?
How does DNA Repair Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “DNA Repair Drugs Industry Forecast” looks at past sales and reviews total world DNA Repair Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected DNA Repair Drugs sales for 2025 through 2031. With DNA Repair Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DNA Repair Drugs industry.
This Insight Report provides a comprehensive analysis of the global DNA Repair Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on DNA Repair Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global DNA Repair Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DNA Repair Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DNA Repair Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of DNA Repair Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
PARP Inhibitors
Other
Segmentation by Application:
Oncological
Stroke
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Key Questions Addressed in this Report
What is the 10-year outlook for the global DNA Repair Drugs market?
What factors are driving DNA Repair Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do DNA Repair Drugs market opportunities vary by end market size?
How does DNA Repair Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
126 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for DNA Repair Drugs by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for DNA Repair Drugs by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
